BioInvent International AB (publ)

34,75

Kursmål for aktien: 69.00 Kr.

Det gennemsnitlige kursmål for BioInvent International AB (publ) aktien er 69.00 Kr. hvilket viser forventningen til aktien indenfor de næste 12 mdr. aktien er undervurderet, da kursmålet ligger under det aktuelle aktiekurs. Aktien er undervurderet med 98,56 % Aktien forventes derfor at stige og være en god investering.

Om BioInvent International AB (publ) aktien

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden. Læs mere
Kr. 2,3B Markedsværdi (Mcap)
Kr. 61,2M Omsætning
Bioteknologi Industri
Sverige Handles på børsen
bioinvent.com Hjemmeside
Sundhed Sektor